JFK Communications has been the PR agency of record for Prometheus Labs and its lead oncology product, Proleukin® (aldesleukin) since 2009. Proleukin (IL-2) is an FDA-approved immunotherapy for the treatment of adults with metastatic renal cell carcinoma and metastatic melanoma.

Throughout our partnership, JFK Communications leads patient advocacy and physician programs designed to engage both audiences regarding treatment options and the potential long-term benefits of Proleukin therapy. In this capacity, JFK Communications provides:

  • Patient Education Workshops/Special Events
  • Patient Advocacy Relations
  • Patient Relations and Education
  • Speaker Training and Compliance
  • Professional/Physician Communications
  • Review and Bylined Articles
  • Press Release Development
  • Trade Media Relations
  • Medical Congress Support
  • Data Communications
  • Advertorial Supplements
  • Web and Digital Media Support

Reach Out

Ready to tell your story?